4D Molecular Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Good afternoon, everyone. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and really pleased to have the 4D Molecular Therapeutics team with us. So maybe to start here, David. I'd have you just introduce the company kind of the situation that's played out through IPO until now with regard to the directed evolution platform, the disease verticals and where we've seen the progress play out across the programs to date.
Perfect. Well, thanks for having us here today. We're pleased to be here. I'm Dave Kirn, Co-Founder and CEO and this is [Julian Pay] , our Head of Investor Relations. So we're thrilled to be here. So 4D Molecular Therapeutics is a next-generation gene therapy company that's built on the power of the directed evolution platform to invent customized AV delivery vectors for any tissue in the body essentially.
And so what this allows us to do is have best
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
